Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice.
Ionotropic gamma-aminobutyric acid (GABA(A)) receptors control the relay of nociceptive signals at several levels of the neuraxis. Experiments with systemically applied benzodiazepines, which enhance the action of GABA at these receptors, have suggested both anti- and pronociceptive effects. The interpretation of such experiments has been notoriously difficult because of confounding sedation. Here, we have used genetically engineered mice, which carry specific benzodiazepine-insensitive GABA(A) receptor subunits, to test whether diazepam, a frequently used classical benzodiazepine, exerts antihyperalgesia after systemic administration in the formalin test, a model of tonic nociception. In wild-type mice, systemic diazepam (3-30 mg/kg, p.o.) dose-dependently reduced the number of formalin-induced flinches during both phases of the test by about 40-70%. This antinociception was reversed by the benzodiazepine site antagonist flumazenil (10mg/kg, i.p.), but fully retained in GABA(A) receptor alpha1 point-mutated mice, which were resistant against the sedative action of diazepam. Experiments carried out in mice with two diazepam-insensitive subunits (alpha1/alpha2, alpha1/alpha3 and alpha1/alpha5 double point-mutated mice) allowed addressing the contribution of alpha2, alpha3 and alpha5 subunits to systemic diazepam-induced antihyperalgesia in the absence of sedation. The relative contributions of these subunits were alpha2 approximately alpha3>alpha5, and thus very similar to those found for intrathecal diazepam (0.09 mg/kg). Accordingly, SL-651498 (10mg/kg, p.o.), an "anxioselective" benzodiazepine site agonist with preferential activity at alpha2/alpha3 subunits, significantly reduced formalin-induced flinching in wild-type mice. We conclude that systemic diazepam exerts a genuine antihyperalgesic effect, which depends on spinal GABA(A) receptors containing alpha2 and/or alpha3 subunits.
Knabl
Julia
J
Institute of Pharmacology and Toxicology, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, D-91054 Erlangen, Germany Laboratory of Genetic Neuropharmacology, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, USA Institute of Pharmaceutical Sciences, ETH Zürich, CH-8057 Zürich, Switzerland.
Zeilhofer
Ulrike B
UB
Crestani
Florence
F
Rudolph
Uwe
U
Zeilhofer
Hanns Ulrich
HU
D000704:Analysis of Variance; D000777:Anesthetics / Q000627:therapeutic use*; D000818:Animals; D001120:Arginine / Q000235:genetics; D003975:Diazepam / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005557:Formaldehyde / Q000009:adverse effects; D006639:Histidine / Q000235:genetics; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D010812:Physical Stimulation; D017354:Point Mutation / Q000235:genetics*; D021122:Protein Subunits / Q000235:genetics; D011758:Pyrroles / Q000627:therapeutic use; D011963:Receptors, GABA-A / Q000235:genetics*
C432169:6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyrido(3,4-b)indol-1-one; D000777:Anesthetics; D007211:Indoles; D021122:Protein Subunits; D011758:Pyrroles; D011963:Receptors, GABA-A; D005557:Formaldehyde; D006639:Histidine; D001120:Arginine; D003975:Diazepam